Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANEB Anebulo Pharmaceuticals	$2.70 +3.8%	$2.11	$0.80 ▼ $3.42	$110.92M	-0.88	168,502 shs	161,524 shs
AQST Aquestive Therapeutics	$3.86 -3.0%	$3.82	$2.12 ▼ $5.80	$384.94M	1.99	1.51 million shs	952,155 shs
AURA Aura Biosciences	$6.52 -0.5%	$6.61	$4.34 ▼ $12.38	$405.02M	0.46	217,557 shs	205,349 shs
CMPS COMPASS Pathways	$4.58 -0.7%	$3.95	$2.25 ▼ $8.54	$439.41M	2.17	1.82 million shs	3.06 million shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANEB Anebulo Pharmaceuticals	0.00%	+4.00%	-18.50%	+132.14%	+24.40%
AQST Aquestive Therapeutics	0.00%	-3.16%	-4.10%	+69.36%	-10.76%
AURA Aura Biosciences	0.00%	-2.53%	-9.41%	+11.21%	-13.70%
CMPS COMPASS Pathways	0.00%	+6.71%	+6.47%	+5.73%	-35.88%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ANEB Anebulo Pharmaceuticals	1.4705 of 5 stars	3.3	3.0	0.0	1.7	0.0
AQST Aquestive Therapeutics	2.1129 of 5 stars	3.4	3.0	3.5	0.0	0.0
AURA Aura Biosciences	1.8072 of 5 stars	3.6	0.0	2.6	2.5	0.0
CMPS COMPASS Pathways	2.2221 of 5 stars	3.4	3.0	1.8	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANEB Anebulo Pharmaceuticals	2.50	Moderate Buy	$5.50	103.70% Upside
AQST Aquestive Therapeutics	2.88	Moderate Buy	$10.14	162.77% Upside
AURA Aura Biosciences	3.11	Buy	$22.00	237.42% Upside
CMPS COMPASS Pathways	2.86	Moderate Buy	$16.29	255.58% Upside

Current Analyst Ratings Breakdown

Latest ANEB, AURA, AQST, and CMPS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/19/2025	AURA Aura Biosciences	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/13/2025	AQST Aquestive Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/13/2025	AURA Aura Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$22.00
8/4/2025	CMPS COMPASS Pathways	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$45.00 ➝ $40.00
8/1/2025	CMPS COMPASS Pathways	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00
7/23/2025	ANEB Anebulo Pharmaceuticals	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/15/2025	CMPS COMPASS Pathways	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$45.00
6/23/2025	CMPS COMPASS Pathways	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
6/23/2025	CMPS COMPASS Pathways	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ In-Line	$11.00 ➝ $6.00
6/17/2025	AQST Aquestive Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
6/2/2025	AQST Aquestive Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$7.00

(Data available from 8/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANEB Anebulo Pharmaceuticals	N/A	N/A	N/A	N/A	$0.15 per share	N/A
AQST Aquestive Therapeutics	$44.13M	8.72	N/A	N/A	($0.66) per share	-5.85
AURA Aura Biosciences	N/A	N/A	N/A	N/A	$3.04 per share	N/A
CMPS COMPASS Pathways	N/A	N/A	N/A	N/A	$2.26 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANEB Anebulo Pharmaceuticals	-$8.20M	-$0.26	N/A	∞	N/A	N/A	-90.11%	-84.53%	9/24/2025 (Estimated)
AQST Aquestive Therapeutics	-$44.14M	-$0.70	N/A	N/A	N/A	-147.38%	N/A	-63.87%	11/3/2025 (Estimated)
AURA Aura Biosciences	-$86.92M	-$1.96	N/A	N/A	N/A	N/A	-64.44%	-54.24%	11/11/2025 (Estimated)
CMPS COMPASS Pathways	-$155.12M	-$1.84	N/A	N/A	N/A	N/A	-87.89%	-57.77%	10/30/2025 (Estimated)

Latest ANEB, AURA, AQST, and CMPS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	AURA Aura Biosciences	-$0.49	-$0.47	+$0.02	-$0.47	N/A	N/A
8/11/2025	Q2 2025	AQST Aquestive Therapeutics	-$0.18	-$0.14	+$0.04	-$0.14	$11.32 million	$10.00 million
7/31/2025	Q2 2025	CMPS COMPASS Pathways	-$0.37	-$0.38	-$0.01	-$0.41	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANEB Anebulo Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
AQST Aquestive Therapeutics	N/A	N/A	N/A	N/A	N/A
AURA Aura Biosciences	N/A	N/A	N/A	N/A	N/A
CMPS COMPASS Pathways	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANEB Anebulo Pharmaceuticals	N/A	25.29	25.29
AQST Aquestive Therapeutics	N/A	3.53	3.18
AURA Aura Biosciences	N/A	12.39	12.39
CMPS COMPASS Pathways	0.16	8.82	8.82

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANEB Anebulo Pharmaceuticals	28.40%
AQST Aquestive Therapeutics	32.45%
AURA Aura Biosciences	96.75%
CMPS COMPASS Pathways	46.19%

Insider Ownership

Company	Insider Ownership
ANEB Anebulo Pharmaceuticals	80.60%
AQST Aquestive Therapeutics	8.35%
AURA Aura Biosciences	6.30%
CMPS COMPASS Pathways	3.93%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANEB Anebulo Pharmaceuticals	4	41.08 million	7.97 million	Not Optionable
AQST Aquestive Therapeutics	160	99.72 million	91.90 million	Optionable
AURA Aura Biosciences	50	62.12 million	58.21 million	Not Optionable
CMPS COMPASS Pathways	120	95.94 million	92.17 million	Optionable

ANEB, AURA, AQST, and CMPS Headlines

Recent News About These Companies

Compass Pathways’ Phase III Study on COMP360: A Potential Game-Changer for Depression Treatment

August 22 at 6:26 PM | msn.com

Compass Pathways’ Phase III Study on COMP360: A Potential Game-Changer for Treatment-resistant Depression

August 20, 2025 | msn.com

COMPASS Pathways PLC Sponsored ADR (NASDAQ:CMPS) Stock Position Increased by Aisling Capital Management LP

August 16, 2025 | marketbeat.com

COMPASS Pathways PLC Sponsored ADR (NASDAQ:CMPS) Shares Bought by Vivo Capital LLC

August 9, 2025 | marketbeat.com

HC Wainwright Cuts Earnings Estimates for COMPASS Pathways

August 8, 2025 | marketbeat.com

Compass Pathways price target lowered to $40 from $45 at H.C. Wainwright

August 6, 2025 | finance.yahoo.com

COMPASS Pathways (NASDAQ:CMPS) Given New $40.00 Price Target at HC Wainwright

August 5, 2025 | marketbeat.com

COMPASS Pathways PLC Sponsored ADR (NASDAQ:CMPS) Stake Lifted by BIT Capital GmbH

August 4, 2025 | marketbeat.com

Compass Pathways: Overly Confident Management Or Overly Skeptical Market

August 3, 2025 | seekingalpha.com

COMPASS Pathways (NASDAQ:CMPS) Releases Earnings Results, Misses Estimates By $0.01 EPS

August 3, 2025 | marketbeat.com

COMPASS Pathways PLC Sponsored ADR (NASDAQ:CMPS) Receives Consensus Rating of "Moderate Buy" from Brokerages

August 3, 2025 | marketbeat.com

Canaccord Genuity Group Reaffirms Buy Rating for COMPASS Pathways (NASDAQ:CMPS)

August 2, 2025 | marketbeat.com

COMPASS Pathways plc (NASDAQ:CMPS) Q2 2025 Earnings Call Transcript

August 1, 2025 | msn.com

Compass (CMPS) Q2 Loss Improves 27%

August 1, 2025 | fool.com

Compass Pathways Announces Second Quarter 2025 Financial Results and Business Highlights

July 31, 2025 | businesswire.com

Compass Pathways Appoints Justin Gover to Board of Directors

July 29, 2025 | businesswire.com

COMPASS Pathways PLC Sponsored ADR (NASDAQ:CMPS) Shares Bought by ARK Investment Management LLC

July 27, 2025 | marketbeat.com

These 2 Stocks Could More Than Double Your Money, According to Wall Street. Is It Time to Buy?

July 20, 2025 | fool.com

Cathie Wood’s ARK Adds 125K COMPASS Pathways plc (CMPS) Shares

July 15, 2025 | msn.com

COMPASS Pathways (CMPS) Upgraded to Buy: Here's Why - Yahoo Finance

July 10, 2025 | finance.yahoo.com

Compass Pathways to Participate in HC Wainwright @Home Series Interview on July 14th, 8:00am ET

July 10, 2025 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ANEB, AURA, AQST, and CMPS Company Descriptions

Anebulo Pharmaceuticals NASDAQ:ANEB

$2.70 +0.10 (+3.85%)

Closing price 04:00 PM Eastern

Extended Trading

$2.66 -0.04 (-1.63%)

As of 06:59 PM Eastern

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is based in Lakeway, Texas.

Aquestive Therapeutics NASDAQ:AQST

$3.86 -0.12 (-3.02%)

Closing price 04:00 PM Eastern

Extended Trading

$3.88 +0.02 (+0.52%)

As of 07:35 PM Eastern

Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. The company's proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.

Aura Biosciences NASDAQ:AURA

$6.52 -0.03 (-0.46%)

Closing price 04:00 PM Eastern

Extended Trading

$6.51 -0.01 (-0.15%)

As of 04:59 PM Eastern

Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.

COMPASS Pathways NASDAQ:CMPS

$4.58 -0.03 (-0.65%)

Closing price 04:00 PM Eastern

Extended Trading

$4.61 +0.03 (+0.55%)

As of 07:57 PM Eastern

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time